Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Standard Biotools (LAB) Research & Development (2016 - 2026)

Standard Biotools has reported Research & Development over the past 16 years, most recently at $8.0 million for Q4 2025.

  • Quarterly Research & Development rose 13.2% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.9 million through Dec 2025, down 14.32% year-over-year, with the annual reading at $26.0 million for FY2025, 9.86% down from the prior year.
  • Research & Development was $8.0 million for Q4 2025 at Standard Biotools, up from $6.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $16.0 million in Q1 2024 and troughed at $6.2 million in Q2 2023.
  • The 5-year median for Research & Development is $7.4 million (2022), against an average of $8.5 million.
  • Year-over-year, Research & Development crashed 50.94% in 2023 and then soared 148.56% in 2024.
  • A 5-year view of Research & Development shows it stood at $9.2 million in 2021, then decreased by 19.37% to $7.4 million in 2022, then fell by 6.95% to $6.9 million in 2023, then grew by 1.9% to $7.0 million in 2024, then rose by 13.2% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Research & Development are $8.0 million (Q4 2025), $6.4 million (Q3 2025), and $6.2 million (Q2 2025).